Skip to main content
Equibles

Boston Partners

Position in HALO — Halozyme Therapeutics, Inc.

CIK 1386060 BOSTON, MA
Back to HALO Full portfolio

Position in HALO

as of Jun 30, 2026 · filed Aug 4, 2026
Position Value
$217,087,166
+$43,640,736 QoQ
Shares Held
2,773,568
+3.3% QoQ
Ownership
2.44%
of shares outstanding
% of Portfolio
0.19%
of 13F equity value
Holder Rank
#7
of 667 holders
Holding Since
Sep 2023
12 quarters on record
Voting authority Sole 93% Shared 0% None 7%

Common Shares in HALO Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

Boston Partners holds $329,375,186 across 6 Biotechnology names. HALO ranks #1 (65.9% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 HALO
Halozyme Therapeutics, Inc.
This page 		2,773,568 $217,087,166
2 PTCT
Ptc Therapeutics, Inc.
 718,574 $58,614,080
3 INVA
Innoviva, Inc.
 1,927,959 $43,783,948
4 BMRN
Biomarin Pharmaceutical Inc
 153,446 $8,780,179
5 HRMY
Harmony Biosciences Holdings, Inc.
 30,481 $1,109,813
6
1,658,936 $0

All Filings in HALO

Export CSV
12 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $217,087,166 2,773,568
2026-03-31 $173,446,430 2,683,683
2025-12-31 $32,779,742 487,069
2025-09-30 $32,621,850 444,803
2025-06-30 $23,376,018 449,366
2025-03-31 $26,565,696 416,325
2024-12-31 $19,505,714 407,984
2024-09-30 $32,738,244 571,947
2024-06-30 $38,178,134 729,147
2024-03-31 $25,643,369 630,368
2023-12-31 $20,416,406 552,392
2023-09-30 $3,186,453 83,415